BioXcel Therapeutics (BTAI) Net Equity Issued and Repurchased (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Net Equity Issued and Repurchased of $8.5 million for Q1 2026, down 39.33% year-over-year from $14.0 million in Q1 2025, and up 47.48% quarter-over-quarter from $5.8 million in Q4 2025.
BioXcel Therapeutics (BTAI) Net Equity Issued and Repurchased (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 39.33% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $52.6 million (up 120.7% YoY), while the FY2025 annual figure was $58.1 million, up 46.5% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $8.5 million, up from $5.8 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $38.2 million in Q3 2025, with the low at $140000.0 in Q2 2025.
- The 4-year median for Net Equity Issued and Repurchased is $7.0 million (2024), against an average of $11.2 million.
- The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased soared 8087.15% in 2025, then tumbled 39.33% in 2026.
- BioXcel Therapeutics' Net Equity Issued and Repurchased stood at $2.4 million in 2023, then soared by 194.78% to $7.0 million in 2024, then declined by 17.7% to $5.8 million in 2025, then jumped by 47.48% to $8.5 million in 2026.
- Business Quant data shows BTAI's Net Equity Issued and Repurchased at $8.5 million in Q1 2026, $5.8 million in Q4 2025, and $38.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | 3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.11 Mn |
| Jun 30, 2026 | 3.11 Mn |
| Mar 31, 2026 | 8.50 Mn |
| Mar 31, 2026 | 8.50 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | 38.23 Mn |
| Sep 30, 2025 | 38.23 Mn |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 14.01 Mn |
| Mar 31, 2025 | 14.01 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Sep 30, 2024 | 467,000.00 |
| Sep 30, 2024 | 467,000.00 |
| Dec 31, 2023 | 2.38 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Mar 31, 2023 | 24.66 Mn |
| Mar 31, 2023 | 24.66 Mn |